Stat3 activation in human endometrial and cervical cancers

C-L Chen1, F-C Hsieh, J C Lieblein

  • 1Center for Childhood Cancer, Columbus Children's Research Institute, Columbus, OH 43205, USA.

British Journal of Cancer
|February 22, 2007
PubMed

Insights

Signal transducer and activator of transcription 3 (Stat3) is activated in endometrial and cervical cancers. Inhibiting Stat3 signaling offers a promising therapeutic target for these cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Signal transducer and activator of transcription 3 (Stat3) is a proto-oncogene implicated in cancer development.
  • Constitutive Stat3 activation is observed in various human cancers, but its role in endometrial and cervical cancers is unexplored.

Purpose of the Study:

  • To investigate the activation status of Stat3 in human endometrial and cervical cancers.
  • To explore Stat3 as a potential therapeutic target in these malignancies.

Main Methods:

  • Examined tyrosine phosphorylation of Stat3 in endometrial and cervical cancer tissues and cell lines using tissue microarrays.
  • Utilized immunohistochemical staining to assess Stat3 activation and downstream gene expression.
  • Employed adenovirus-mediated gene transfer of a dominant-negative Stat3 mutant and a JAK/Stat3 inhibitor (JSI-124) to evaluate therapeutic efficacy.

Main Results:

  • Elevated Stat3 phosphorylation was detected in both endometrial and cervical cancer cell lines and patient specimens.
  • Activated Stat3 correlated with increased expression of antiapoptotic genes (Bcl-xL, survivin, Mcl-1).
  • Inhibition of Stat3 signaling via gene transfer or a small molecule inhibitor induced apoptosis and suppressed cell growth in cancer cell lines.

Conclusions:

  • Stat3 is constitutively activated in human endometrial and cervical cancers.
  • Targeting Stat3 signaling represents a potential therapeutic strategy for endometrial and cervical cancer intervention.

Related Concept Videos